Short summary

The use of checkpoint-inhibitors (CPI) have improved the survival for patients with melanoma significantly. Hovever, immune related adverse events are common, with immune related diarrhoea/colitis (ir-colitis) being among of most frequent. This retrospective study aims to describe the course of patients afflicted with ir-colitis, with a particular focus on administration of immunosuppressive drugs, the necessity for hospitalization and the overall symptom burden.

Description of the cohort

The study population consist of melanoma patients who have been treated with CPI and subsequently devolved ir-colitis within the Department of Oncology at OUH. Data are retrospectively collected from December 2013 to December 2023.

Data and biological material

All data, including patient and tumor characteristics, are planned to be extracted from the patients' electronic medical records and the national database for metastatic melanoma (DAMMED).

Collaborating researchers and departments

Department of Oncology, OUH

• Christina Ruhlmann
• Lars Bastholt

Department of gastroenterology, OUH

• Jens Kjeldsen

Department of Biochemistry, OUH

• Pernille Just

OPEN, OUH

• Sören Möller